Tevogen Bio Stock Price, News & Analysis

Tevogen (Nasdaq: TVGN) honored board member Curtis Patton, PhD, with a joint portrait at Yale School of Medicine recognizing his decades-long contributions to medical education, mentorship, and public health.

The portrait by Mario Moore will be unveiled on December 11, 2025 at 4 p.m. at the Harvey Cushing/John Hay Whitney Medical Library. Tevogen highlighted Dr. Patton's influence on the company as it advances the ExacTcell™ T cell platform, scales Tevogen.AI predictive technologies, and pursues growth with revenue forecasts exceeding $1 billion.

Tevogen (Nasdaq: TVGN) was named to the 2025 New Jersey Power List by NJBIZ for influence on New Jersey's economic and innovation landscape.

NJBIZ highlighted Tevogen's ExacTcell platform, advancing pipelines in infectious disease, oncology, and neurology, and its internally developed PredicTcell AI for target prediction. The recognition referenced an anticipated ~$1 billion in first-year specialty-care revenue and a cumulative five-year forecast of $18–22 billion. Tevogen also noted expansion including a 17,428-square-foot manufacturing facility and a new headquarters that more than doubles its prior footprint, centralizing R&D, regulatory, and Tevogen.AI operations.

Tevogen (Nasdaq: TVGN) filed its Form 10-Q for the quarter ended September 30, 2025, reporting continued capital-efficient execution.

Key metrics: GAAP loss from operations of $5.7M for Q3 2025 and $21.5M for the nine months ended Sept 30, 2025; Adjusted loss from operations was $2.5M (Q3) and $7.8M (nine months), representing a 10% and 25% reduction versus the comparable 2024 periods. The company highlights investments in workforce, IT, and Tevogen.AI while emphasizing cost-efficient drug development.

Tevogen (Nasdaq: TVGN) announced on Nov 5, 2025 completion of T cell target identification for five additional HLA restrictions, expanding ExacTcell™ coverage beyond the initial HLA-A*02:01.

The company says the step could extend TVGN 489 access from ~25% to approximately 65% of the U.S. population. The TVGN 489 proof-of-concept trial reported 100% viral clearance, no reinfections, and no Long COVID cases in high-risk patients.

Tevogen (Nasdaq: TVGN) clarified its reported accumulated deficit and provided cash-versus-noncash context for investors on Nov 3, 2025. The company said it has raised under $42 million in total cash to June 30, 2025, while GAAP shows an accumulated deficit of $129 million. Management explained that backing out cash yields a cash loss of ~ $41 million and about $88 million of non-cash expenses, offset by $110 million in Additional Paid-in Capital and a capital raise of over $8.8 million, leaving a stockholders’ deficit of under $9.5 million.

The company plans to publish reconciled non-GAAP metrics with its Form 10-Q for Q3 2025 and reiterated forward-looking risks including the need for additional capital.

Tevogen (Nasdaq: TVGN) outlined recent progress in making allogeneic T cell therapies more accessible, citing dose-finding clinical data for TVGN 489 and demand from Long COVID patients. Management highlighted an rNPV valuation of $9–$11 billion for TVGN 489 and a projected 5-year top-line revenue of ~ $6.5 billion for a liver-cancer prevention product targeting high-risk chronic Hepatitis B. Tevogen.AI completed alpha and began beta of PredicTcell, reported large time reductions in target analysis with potential billions in development savings, and received an international patent publication (WO2025/129197). The company expanded headquarters and created a Long COVID contact channel receiving global inquiries.

Tevogen (Nasdaq: TVGN) provided an update on its investigational precision T cell therapy TVGN 489 on Oct 15, 2025, citing growing public interest from Long COVID patients and stakeholders.

The company said a dose-finding clinical trial showed a favorable safety profile and was peer-reviewed and published in Blood Advances. Tevogen plans collaborations with government programs, patient organizations, and major healthcare providers to expedite development and access when regulatory pathways permit, and has created a dedicated Long COVID contact at longCOVID@tevogen.com. The company also stated it is maximizing capital efficiency and maintains access to financing to support advancement toward commercialization.

Tevogen (NASDAQ:TVGN) announced significant advancements in its PredicTcell™ AI platform for T cell-based therapies. The beta version has expanded its training dataset to ~1.4 million records and total dataset to over 6.7 billion records, marking a 100-fold increase.

The platform, developed with Microsoft and Databricks, builds upon the alpha version which achieved 92-97% recall levels and 38-43% precision. The beta version analyzes over 10.7 billion data points, including 6.5 billion virology, 4.2 billion genomic, and 416 million oncology datapoints, while expanding training features from 22 to 27.

This advancement could potentially enable T-cell therapies to bind to their targets with unprecedented accuracy, promising increased clinical success rates, shorter development timelines, and improved patient access to life-saving therapies.

Tevogen Bio (NASDAQ:TVGN) has highlighted the potential of its investigational T cell therapy TVGN 489 in treating Long COVID, which affects an estimated 20 million Americans. Recent peer-reviewed studies have linked Long COVID to persistent viral reservoirs, where SARS-CoV-2 proteins and RNA remain in the body for months to years after infection.

TVGN 489, developed using Tevogen's ExacTcell™ platform, is an off-the-shelf cytotoxic CD8+ T lymphocyte therapy targeting multiple SARS-CoV-2 proteins. In proof-of-concept trials, the therapy demonstrated efficacy in reducing viral load in all patients, with CTLs persisting for at least 6 months without interfering with patients' immune responses.

The company is actively preparing for clinical manufacturing of TVGN 489, which could potentially restore homeostasis in Long COVID patients by eliminating virus-infected cells.